Resources for Investors

Due diligence frameworks and strategic intelligence for evaluating CGT assets

Published reports

GTC Insight Report

Lock the Rights Before You Lock the Vector

A 12 question vector rights self-assessment and six steps to prepare a decision record with your IP/patent counsel.

Due Diligence

Case Study

FDA's New Rulebook for N=1: Due Diligence Implications

Why RMAT and BTD status are no longer the de-risking signals investors thought. The Plausible Mechanism Pathway changes how you evaluate gene therapy assets.

Dr. Rahul Kaushik November 2025

Need Personalized Guidance?

Our expert consultants are ready to help you evaluate your pipeline and develop winning investment strategies.

Book a Free Discovery Call